Genmab: Phase 3 study closed enrollment, 621 enrolled (Head and Neck Squamous Cell Carcinoma)
Genmab: Phase 3 study closed enrollment, 621 enrolled (Head and Neck Squamous Cell Carcinoma). Its enrollment of 621 is top-decile (91st percentile of 8,879 records). Dated 2 days ago, it is inside the fresh trigger window. Score 100/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 621 · 91th percentile of 8,879 ClinicalTrialStartPulse records · 7.8x the median
Free preview: all 15 published fields of this record are shown below. Locked: 499 related US ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Genmab |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2) |
| NCT ID | NCT06496178 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Head and Neck Squamous Cell Carcinoma |
| Intervention types | drug |
| Target enrollment | 621 |
| Site countries | United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Greece, Hungary |
| Posted | 2024-07-11 |
| Planned start | 2024-06-25 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-11-02 |
| Last update posted | 2026-11-02 |
| enrollment percentile | 91th of 8,879 (median 80, 7.8x median) |
| Peer records CSV (500 US records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Genmab
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Genmab + 500 US peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-11-02
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (US first): Sanofi · Pfizer · National Institute of Arthritis and Musculoskeletal and Skin · Apple Inc. · National Cancer Institute (NCI) · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Genmab and 2,512 US peers
- US ClinicalTrialStartPulse records like this one: 2,512
- Genmab's enrollment: 91st percentile of 8,879 records
- Timing: High: dated in the last 7 days
- Estimated pipeline if you contact every US peer: $502,400 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
100 / 100 Score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 621 participants planned.
What is the ClinicalTrialStartPulse record for Genmab?
Genmab's Phase 3 study (NCT06496178) in Head and Neck Squamous Cell Carcinoma, first posted 2024-07-11: enrollment closed (active, not recruiting) (2026-11-02), in an update posted 2026-11-02.
How does Genmab compare to other ClinicalTrialStartPulse records?
This is a top-decile record: its enrollment of 621 is 7.8x the median of 80 across 8,879 records. It is fresh: dated 2 days ago, inside the window where early outreach matters most. Its Score of 100/100 puts it among the stronger signals in this feed.
Genmab vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Genmab | US | 621 | 91st | 2026-11-02 |
| Janssen Research & Development, LLC | US | 539 | 90th | 2026-11-03 |
| Janssen Research & Development, LLC | US | 743 | 92nd | 2026-11-03 |
| Janssen Research & Development, LLC | US | 864 | 93rd | 2026-11-03 |
Related records
ClinicalTrialStartPulse: Phase 3 ClinicalTrialStartPulse: United States sites
More US public-record feeds
U.S. DOT Injury/Illness Summary Pulse in US U.S. DOT FRA Regulated Mode Major Security Events Pulse in US U.S. DOT Crossing Inventory Data Pulse in US U.S. DOT Insur - All With History Pulse in US USAC Telecom CAF Locations Obligation and Deployment by Speed Tier Data Pul in US U.S. CDC 2022 Final Assisted Reproductive Technology Summary Pulse in US U.S. DOT Rail Equipment Accident/Incident Data Subset Pulse in US U.S. DOT Monthly Modal Time Series Pulse in US
How to monitor Genmab and peer phase 3 records
Get new ClinicalTrialStartPulse records like Genmab by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.